Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Low molecular weight heparins
- Indications Deep vein thrombosis; Thromboembolism
- Focus Therapeutic Use
- Acronyms Cancer-DACUS
Most Recent Events
- 21 Feb 2011 Status changed from recruiting to completed.
- 04 Mar 2009 Biomarkers information updated
- 03 Mar 2009 Planned end date (Mar 2011) added as reported by ClinicalTrials.gov.